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Recurrent thrombosis in patients with 
antiphospholipid antibodies treated with vitamin K
antagonists or rivaroxaban
Antiphospholipid antibodies (aPL) include lupus anti-
coagulant (LA), anticardiolipin antibodies (aCL) and anti-
β2 glycoprotein I antibodies (aβ2-GPI). This condition is
a severe acquired thrombophilia associated with an
increased risk of venous and arterial thrombosis and
adverse pregnancy outcome.1 The presence of aPL and
clinical manifestations define the antiphospholipid syn-
drome (aPS).2 Patients with persistent laboratory evi-
dence of aPL require long-term anticoagulant therapy
after the first thrombotic episode, particularly those with
triple aPL positivity.3 The drugs of choice are the vitamin-
K antagonists (VKA) at adjusted doses to maintain an
international normalized ratio (INR) between 2.0 and 3.0.
Despite VKA therapy, the risk of recurrent thrombosis
remains high, varying from 3 to 24%4,5 and even increas-
ing the intensity of therapy to an INR of 3.0-4.0 does not
reduce the probability of recurrence.4,6 Direct oral antico-
agulant (DOAC) drugs represent a valid and safe antico-
agulant alternative to VKA and their use has been sug-
gested also in patients with aPS,7-9 although several
reports raised safety issues.10 To  investigate the recurrent
rate of thrombosis in patients with aPS treated with VKA
or DOAC we followed our cohort diagnosed from 2013,
year of the introduction of the first DOAC (rivaroxaban)
on the Italian market for the treatment and secondary
prevention of venous thromboembolism.
Patients consecutively referred to our Thrombosis
Center for a thrombophilia workup from September
2013 to December 2016 after an episode of objectively
documented venous thrombosis  formed the initial study
population. Those who tested positive for the presence
of aPL were followed to investigate the risk of recurrent
thrombosis and the risk of bleeding. The latter was clas-
sified as major or minor according to the definition of the
International Society of Thrombosis and Haemostasis
(ISTH).11 Patients on VKA monitoring INR at our
Thrombosis Center were interviewed at any blood sam-
pling and those who were monitoring INR at other sites
or those on DOAC were interviewed by telephone every
three months by one of us (IM, MA) for the occurrence
of recurrent thrombosis and bleeding episodes, and invit-
ed to come back to the Center with the objective docu-
mentation of the events (deep vein thrombosis of the
limbs, pulmonary embolism, cerebral or splanchnic vein
thrombosis, acute myocardial infarction, transient
ischemic attack, ischemic stroke).  Patients were followed
from the starting date to the end of anticoagulant therapy
with VKA or DOAC, or to the date of recurrent throm-
bosis, major bleeding or May 15, 2017 (administrative
censoring). In case of switching therapy from VKA to
DOAC or vice versa, patients were considered separately
for each period of drug intake. The Institutional Review
Board of the Hospital approved this study and patients
gave their written informed consent to participate. aPL
were evaluated as recommended by the Subcommittee
on Lupus  Anticoagulant/Phospholipid/Dependent
Antibodies of the ISTH.12  Details on laboratory tests and
statistical analysis can be found in the Online
Supplementary Appendix.
In the study period, 672 patients with venous throm-
bosis were referred to the Center. Twenty-eight of them
(4.2%) had confirmed aPS with at least one positivity for
LA, aCL or aβ2-GPI. Their general characteristics at index
event are shown in Table 1. Fifteen patients took VKA
and 13 took DOAC  (rivaroxaban in all cases). The reason
for choosing one or the other treatment was based only
on physicians’ and patients’ preference. Nearly half of the
patients on both treatment groups had triple positivity
for LA , aCL and aβ2-GPI, and the other risk factors for
thrombosis were also similarly distributed. Rivaroxaban
was the first anticoagulant therapy in 9 patients (15 mg
bid for 21 days followed by 20 mg od), whereas 4
switched from VKA to rivaroxaban (20 mg od) at  their
own request. No patient switched from rivaroxaban to
VKA. Four patients ended oral anticoagulant therapy
because of  pregnancy (switch to LMWH), patient’s
choice, post-traumatic event and decision of general prac-
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Table 1. Baseline characteristics at index event of the 28 patients
with antiphospholipid syndrome.
Patients on vitamin K Patients on
antagonists rivaroxaban*
N. 15 13
Men/Women 10/5 9/4
BMI, kg/m2, mean (SD) 26.8 (3.9) 28.3 (3.2)
Age at thrombosis, years, mean (SD) 43.1 (15.8) 46.2 (16.4)
Index event, n (%)
Deep vein thrombosis 11 (80) 8 (61.5)
Pulmonary embolism 2 (13.3) 1 (7.7)
Both 2 (13.3) 4 (30.8)
Antiphospholipid profile, n (%) 
Lupus anticoagulant 3 (20) 7 (53.8)
Anticardiolipin antibodies† 2 (13.3) -
Anti- 2 glycoprotein I antibodies‡ 1 (6.7) -
Double positivity§ 2 (13.3) -
Triple positivity 7 (46.7) 6 (46.2)
Risk factors for venous thrombosis, n (%) 
None 3 (20) 5 (38.5)
Cancer 1 (6.7) -
Immobilization 1 (6.7) 1 (7.7)
Trauma 3 (20) 2 (15.4)
Infection 2 (13.3) 1 (7.7)
Oral contraceptive use 2 (13.3) 2 (15.4)
Pregnancy/puerperium - 1 (7.7)
Autoimmune disease 2 (13.3) 3 (23.1)
Cardiovascular risk factors, n (%) 
None 11 (73.3) 9 (69.2)
Diabetes - 1 (7.7)
Hypertension 4 (26.7) 2 (15.4)
Dyslipidemia 1 (6.7) -
Smoking 1 (6.7) 1 (7.7)
Inherited thrombophilia abnormalities, n (%)
None 14 (93.3) 13 (100)
AT,  PC or PS deficiency 1 (6.7) -
Factor V Leiden 1 (6.7) -
G20210A prothrombin mutation - -
N, n: number; SD: Standard Deviation; BMI: body mass index; AT: antithrombin; PC:
protein C; PS: protein S; aCL: anticardiolipin antibodies. *Nine patients received
only rivaroxaban and 4 shifted from vitamin K antagonists to rivaroxaban. †IgM
(both patients). ‡IgG: §Lupus anticoagulant and anti-β2 glycoprotein 1 (aβ2-GPI)
antibodies IgG and IgM; anticardiolipin IgG and anti-β2 glycoprotein 1 antibodies
IgG, all at medium-high titer (>40 GPL or MPL for aCL and >10 U/mL for aβ2-GPI).
titioner.  Patients who took both drugs were counted in
the two treatment groups for the respective periods of
treatment, for a total of 20 periods for VKA and 13 peri-
ods for rivaroxaban. Mean follow up was 21.9 [Standard
Deviation (SD) 12.9] months for all aPS patients, 23.6 (SD
13.2) months in VKA (41.3 patient years) and 19.0 (SD
12.3) months in rivaroxaban (20.6 patient years). 
Five patients experienced recurrent thrombosis, one on
VKA for an incidence rate of  2.4 (95%CI: 0.2-11.3) per
100 patient years and 4 on rivaroxaban for an incidence
rate of  19.4 (95%CI: 6.5-46.2) per 100 patient years. The
INR of the patient on VKA in the week before recurrence
was 3.8. Figure 1 shows the Kaplan-Meier curves of
recurrent thrombosis according to the type of anticoagu-
lant therapy. The cumulative incidence at 24 months of
follow up was 42% (95%CI: 8.3-75.7) in patients on
rivaroxaban and 7.1% (95%CI: 1-41) in those on VKA
and the HR for recurrent thrombosis in patients on
rivaroxaban versus those on VKA was 7.53 (95%CI: 0.84-
67.6). After 24 months of follow up no recurrence was
observed for the entire observational period of 48
months for patients on VKA and 43 months for patients
on rivaroxaban. Table 2 shows the detailed characteris-
tics of patients with recurrent thrombosis. Recurrent
events were arterial in 4 patients (3 acute myocardial
infarction and one cerebral ischemic stroke of non-car-
dioembolic origin) and venous in one (cerebral vein
thrombosis). All patients with recurrent thrombosis had
triple positivity for LA, aCL and aβ2-GPI and none was
taking antiplatelet together with oral anticoagulant ther-
apy. Other than aPS, no other thrombophilia markers nor
additional risk factors for thrombosis (cancer, immobi-
lization, trauma, infection, oral contraceptive use,
autoimmune disease, diabetes, hypertension, dyslipi-
demia, smoking) were recorded, apart from type 2 dia-
betes poorly controlled by non-insulin glucose-lowering
drugs in the patient with recurrent stroke. All patients
were overweight or had class 1 obesity.  No patient had
major or clinically relevant non-major bleeding during
follow up.
To date, data on efficacy and safety of DOAC in
patients with aPS are limited and controversial.  The only
randomized controlled trial of 116 patients with aPS
observed a higher endogenous thrombin potential in
those receiving rivaroxaban than VKA, although there
was no recurrent VTE during six months of follow up.
However, the proportion of triple positivity aPS was low
(12% in rivaroxaban and 20% in the VKA arm).13 A
recent review of studies in patients with aPS and recur-
rent thrombosis while on DOAC reported 19 recurrent
arterial or venous thrombosis out of 122 patients (15.6%)
during a mean observation time of 12.6 months.10 The
aPL profile was not available for all patients, but appar-
ently half of recurrent thrombosis occurred in aPS
patients with triple positivity. A low frequency of recur-
rence was observed in a cohort study of patients at low
risk for single or double positivity aPS.14 In our study,
nearly half the patients in both treatment groups, VKA or
rivaroxaban, had triple positivity and all recurrent events
were observed in such patients. In addition, the similar
characteristics of patients in the two treatment groups
make the risk of confounding by indication unlikely.
Apart from overweight or class 1 obesity, no systemic
risk factors for thrombosis other than triple positivity aPS
were observed in patients with recurrent events. 
Some limitations of our study need to be discussed.
First, the small sample size does not allow us to draw
firm conclusions or to speculate on the excess of arterial
over venous recurrent thrombosis, despite the fact that
all index events were venous. Second, since all our
patients on DOAC took rivaroxaban, which remains the
most widely prescribed given that it first came on the
Italian market as treatment of venous thromboembolism,
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Figure 1. Cumulative incidence of recurrent thrombosis according to antico-
agulant therapy. VKA: vitamin K antagonists.
Table 2. Characteristics of patients with recurrent thrombosis during anticoagulant treatment. 
#1 #2 #3 #4 #5
Type of anticoagulant therapy Rivaroxaban Rivaroxaban Rivaroxaban Rivaroxaban VKA
Sex M M M F M
Antiphospholipid profile Triple positivity Triple positivity Triple positivity Triple positivity Triple positivity
Age at index event, years 67 47 28 37 35
Type of index event DVT DVT DVT+PE DVT DVT
Switch from VKA to rivaroxaban No No Yes No No
Time on anticoagulant treatment until recurrence 23 months 1 month 21 months 4 months 22 months
Age at recurrent thrombosis, years 69 47 37 37 39
BMI, kg/m2 27.4 30.2 30.7 27.5 26.7
Type of recurrent thrombosis Stroke AMI AMI CVT AMI
VKA: vitamin K antagonists; M: male; F: female; BMI: body mass index; DVT: deep vein thrombosis; PE: pulmonary embolism; AMI: acute myocardial infarction; CVT: cerebral
vein thrombosis.
our results cannot be generalized to other DOAC. Third,
diagnosis of LA is sometimes critical in patients on
DOAC because of their influence on the diluted Russel
viper venom test. We are confident that we did not have
false positive aPS diagnosis because the 7 patients with
LA and without  aCL or aβ2-GPI antibodies also had pos-
itive silica clotting time. Finally, since our study was not
designed as a randomized trial, no surrogate marker for
recurrent thrombosis was considered.  We do not have
information on time in therapeutic INR range, anti-Xa
activity nor real drug intake of our patients, and therefore
the possibility of scarce compliance in patients with
recurrent thrombosis cannot be ruled out. 
In conclusion, the limited experience on the use of
DOAC in clinical practice and data from real-life clinical
practice are not sufficient to establish whether they are
equally effective as VKA in treatment and secondary pre-
vention of thrombosis in patients at very high thrombotic
risk, such as those with aPS. We observed an increased
risk of recurrent thrombosis in patients with triple posi-
tivity aPS treated with rivaroxaban compared to those
treated with VKA and this provides further insights into
the post-market surveillance of DOAC. Although the
combination of low-dose rivaroxaban and acetylsalicylic
acid reduces morbidity and mortality of coronary artery
disease in non-aPS patients,15 there is no evidence of the
efficacy of rivaroxaban alone in preventing arterial
thrombosis.  While awaiting the results of an ongoing
randomized controlled trial (clinicaltrials.gov identifier:
02157272), we suggest caution in prescribing rivaroxa-
ban to patients with triple positivity aPS. 
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